Panion & BF Biotech Inc
Panion & BF Biotech Inc develops and commercializes biopharmaceutical products, primarily in the oncology and autoimmune disease treatment markets.
Business. Panion & BF Biotech Inc (1760.TW) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is listed on the Taiwan Stock Exchange and operates within the broader pharmaceuticals and medical research sector. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the pharmaceutical product-sale market.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Panion & BF Biotech Inc (1760.TW) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is listed on the Taiwan Stock Exchange and operates within the broader pharmaceuticals and medical research sector. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the pharmaceutical product-sale market.
The company maintains a conservative capital structure with a debt-to-equity ratio of 0.33, well below the industry median of 0.65. However, its liquidity position is constrained by negative net cash of TWD 631,604,000 when considering TWD 647,704,000 in long-term debt against TWD 15,709,000 in cash and equivalents. The current ratio of 1.45 suggests adequate short-term liquidity, but the free cash flow of TWD 15,919,000 represents only 5.1% of operating cash flow, indicating limited capacity for debt reduction or shareholder returns.
Profitability metrics show mixed performance relative to industry benchmarks. Return on equity of 9.73% exceeds the pharmaceutical industry median of 8.2%, but return on assets of 5.89% lags behind the 7.1% median. Gross margin of 54.1% (TWD 1,116,851,000 gross profit on TWD 2,063,392,000 revenue) is in line with sector norms, but operating margin of 14.9% (TWD 307,957,000) is below the 17.3% median.
Geographic and segment exposure is concentrated in a single business line, with no disclosed revenue diversification across therapeutic areas or regions. This lack of segmentation reporting limits visibility into growth drivers and risk distribution.
Revenue growth has been modest, with the most recent period showing TWD 2,063,392,000 in revenue. While the company has maintained positive net income of TWD 190,169,000, capital expenditures of TWD -158,339,000 suggest ongoing investment in R&D or manufacturing capabilities.
The risk profile includes medium liquidity risk due to negative net cash and low dilution risk based on current share counts. No material dilution is indicated by the identical basic and diluted share counts of 85,739,000 shares. The risk assessment flags net cash negativity as a key concern, though no specific debt covenants or maturity schedules are disclosed.
Recent analyst coverage shows consensus on a TWD 82.00 price target with one "hold" recommendation and no "buy" or "strong buy" ratings. This suggests limited upside potential in the near term.
- Conservative debt levels but negative net cash position raises liquidity concerns
- ROE outperforms industry median but ROA underperforms
- No geographic or product segmentation reported, limiting risk visibility
- Analysts show neutral sentiment with no upside bias in price targets
- Capital expenditures suggest ongoing investment in growth initiatives
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,83 |
| Revenue | —no estimate | —no estimate | 2,1B TWD |
| Operating income | —no estimate | —no estimate | 270,0M TWD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Panion & BF Biotech Inc Market data — financials · 2026-05-26
- Panion & BF Biotech Inc Market data — analyst estimates · 2026-05-26